tirzepatide liver damage Let’s talk about and fatty disease. #tirzepatide #mounjaro Stitch: @drjennahsiwak Tirzepatide for weight loss treats

Wegovy works by: Slowing gastric emptying, which prolongs feelings of fullness Acting on appetite centres in the brain to reduce hunger Reducing food intake and caloric consumption Clinical trials have demonstrated that semaglutide, when combined with lifestyle interventions, can lead to significant weight losswith mean reductions of approximately 15% in non-diabetic adults (STEP 1 trial) and around 10% in people with type 2 diabetes (STEP 2 trial) over 68 weeks

rare adverse events not yet detectable from smaller trial populations Limitation : Phase 2 safety data insufficient for comprehensive risk-benefit assessment Dosing and Administration Comparison# Semaglutide Dosing# Survodutide Dosing# Use Case Recommendations# Choose Semaglutide When:# Proven efficacy with FDA-approved dosing is required for current clinical use Cardiovascular risk reduction is a treatment goal (SELECT trial evidence) Oral dosing is preferred (Rybelsus option) Comprehensive safety data and well-characterized risk profile are priorities Type 2 diabetes is the primary indication alongside weight management Choose Survodutide When:# MASH/NASH is a primary treatment target, where glucagon-mediated hepatic fat oxidation provides a differentiated mechanism Maximum weight loss beyond GLP-1 monotherapy is the goal, pending Phase 3 confirmation Energy expenditure enhancement is desired alongside appetite suppression Clinical trial participation is an option for accessing the compound before potential approval Can They Be Combined?# Combining semaglutide with survodutide is not pharmacologically rational, as survodutide already contains GLP-1R agonist activity

Approximately 150 kcal

When used appropriately, BPC-157 can be an effective part of a comprehensive approach to injury recovery, gut health, and long-term performance